Replies to post #27965 on Ayala Pharmaceuticals Inc (ADXS)

[jckrdu]

Milestones on slide 50 of latest corporate deck:
Prelim Data A+B H2 2017* Metastatic Prostate Cancer
ADXS-PSA Phase 1/2 Combination ± KEYTRUDA® (pembrolizumab)
http://www.advaxis.com/wp-content/uploads/2017/06/July-2017-Corporate-Presentation.pdf

From June 13, 2017 PR:
Early data on the first few patients treated with ADXS-PSA in combination with Keytruda suggested that the combination may lead to the emergence of a larger number of expanded and new T cell clones, especially over the first few treatments, thereby increasing the frequency of expanded T cells that can persist. This T cell clone expansion and persistence effect correlates with stabilization of disease. These findings and additional correlative immunologic data from this ongoing trial have been submitted for presentation at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in Frankfurt, Germany, in September. Dr. Stein also detailed plans to initiate an investigator sponsored trial of ADXS-PSA in patients with earlier stage prostate cancer.
http://ir.advaxis.com/press-releases/detail/1273/advaxis-details-registrational-trials-eu-regulatory-and

I just started following ADXS more closely recently, so others may have additional or more current info. It's not clear to me if the 2 items above are the same thing (i.e. the data milestone guided for "H2 2017" is referring to the data submitted for the September 2017 AACR conference.)